Skip to main content

Advertisement

Table 2 Baseline demographic characteristics according to follow-up groups

From: The effect of stimulation therapy and donepezil on cognitive function in Alzheimer’s disease. A community based RCT with a two-by-two factorial design

Groups Age ± SD* Gender Education Living   
   Female ≤ 7 yerars Couple Comorbidity Drug use
   n (%) n (%) n (%) ± SD* ± SD*
Municipality       
Stimulation 81.6 ± 6.7 59(57) 88(85) 48(46) 1.82 ± 1.7 4.89 ± 3.3
Standard care 4.89 ± 3.3 54(65) 65(79) 37(45) 1.65 ± 1.1 5.40 ± 3.9
p-value 0.12 0.25 0.34 0.83 0.45 0.34
Drug       
Donepezil 80.80 ± 6.8 62(67) 82(89) 39(42) 1.90 ± 1.7 5.10 ± 3.3
Placebo 80.85 ± 7.3 50(54) 70(75) 46(49) 1.59 ± 1.2 5.16 ± 3.8
p-value 0.96 0.07 0.014 0.30 0.15 0.90
Combination       
Donepezil + stimulation 81.32 ± 7.0 31(60) 47(90) 28(54) 2.02 ± 2.0 4.92 ± 2.8
Placebo + Standard care 79.81 ± 8.1 22(54) 29(71) 19(46) 1.51 ± 1.1 5.41 ± 3.9
p-value 0.34 0.57 0.015 0.47 0.14 0.48
Head to head       
Stimulation therapy 81.89 ± 8.3 27(53) 40(78) 24(47) 1.61 ± 1.4 4.88 ± 3.7
Donepezil 80.17 ± 6.4 28(74) 32(86) 15(39) 1.76 ± 1.3 5.26 ± 4.0
p-value 0.21 0.046 0.33 0.45 0.61 0.65
  1. *Mean values ± standard deviation.